Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Reimbursement request list for companion diagnostics and personalized medicine updated in Belgium

In September 2020, the list of companion diagnostic tests, which are evaluated for reimbursement, was updated. INAMI has a specific reimbursement framework for companion diagnostic tests. INAMI Nomenclature codes from Article 33ter can only be reimbursed in relation to specific biomarker tests and drugs from Chapter VIII of the reimbursable pharmaceutical specialties (Royal Decree of February 1, 2018).

The updated list of molecular companion diagnostics (accompanied by appropriate active ingredient) for which a reimbursement application has been made (with the month of the application) is presented below:

  • ALK - Lorlatinib (August 2019)
  • FLT3-TKD and FLT3-ITD - Gilteritinib (October 2019)
  • NTRK - Larotrectinib (October 2019)
  • BCR/ABL1 - Dasatinib (November 2019)
  • TP53 and 17p deletion - Venetoclax + Obinutuzumab (April 2020)
  • BRAF V600 - Trametinib + Dabrafenib (June 2020)
  • ALK - Brigatinib (June 2020)
  • PIK3CA - Alpelisib (July 2020)

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.